Getein Biotech Inc

Getein Biotech released its 2026 interim report on August 27, 2026. During the reporting period, the company's total operating revenue was 555 million yuan, net profit attributable to the parent company was 184 million yuan, and net cash inflow from operating activities was 189 million yuan. The company's latest asset-liability ratio was 19.21%, and gross margin was 69.09%, down 1.25 percentage points from the previous quarter and down 0.27 percentage points from the same period last year. The latest return on equity was 6.27%. Diluted earnings per share were 0.36 yuan, total asset turnover was 0.15 times, and inventory turnover was 0.92 times. The company had 30,700 shareholders, and the top ten shareholders held 245 million shares, accounting for 48.39% of total share capital.

Getein Biotech announced on August 26 that it plans to distribute a cash dividend of 0.15 yuan per share, before tax, to all shareholders, with an estimated total payout of 75.97 million yuan, accounting for 41.22% of net profit attributable to the parent company. In the first half of 2026, the company achieved revenue of 555 million yuan and net profit attributable to the parent company of 184 million yuan.

Getein Biotech released its 2026 interim report. First-half net profit attributable to the parent was 184 million yuan, up 69.4% year on year. Operating revenue was 555 million yuan, up 8.3% year on year. Net profit attributable to the parent after deducting non-recurring items was 118 million yuan, up 26.6% year on year. Net operating cash flow was 189 million yuan, up 28.1% year on year. In the second quarter, net profit attributable to the parent was 108 million yuan, up 142.7% year on year. The company said sales of core products such as point-of-care testing and chemiluminescence grew significantly, driving revenue higher. At the same time, it completed the transfer of a 56.9766% stake in its subsidiary Wuhan Jingchuan Diagnostic Technology, which had a positive impact on net profit.

Getein Biotech has released its earnings forecast, projecting attributable net profit for the first half of 2026 at 170 million to 200 million yuan, a year-on-year increase of 56.24% to 83.81%. Deducted non-recurring net profit is expected to be 110 million to 130 million yuan, up 17.99% to 39.44%. The company said the profit growth is mainly due to enhanced competitiveness in overseas markets, with significant sales increases in core products such as point-of-care testing and chemiluminescence, driving higher operating revenue. In addition, the company completed the transfer of its 56.9766% stake in subsidiary Wuhan Jingchuan Diagnostic Technology, which contributed approximately 49.04 million yuan to net profit.

Getein Biotech announced plans to repurchase shares through centralized bidding. The total buyback amount will be no less than 50 million yuan and no more than 100 million yuan, with a maximum price of 12.51 yuan per share. The company expects to buy back between 4 million and 7.99 million shares, representing 0.79% to 1.58% of total share capital. The buyback period is 12 months following board approval, and the repurchased shares will be used for employee stock ownership plans or equity incentives. In the first quarter of 2026, the company reported revenue of 268 million yuan and net profit attributable to shareholders of 76.3 million yuan.